10
Participants
Start Date
October 29, 2018
Primary Completion Date
January 12, 2022
Study Completion Date
January 12, 2022
AMG 562
AMG 562 is a BiTE® antibody construct that targets CD19 and is intended for the treatment of patients with B-cell malignancies.
Universitair Ziekenhuis Leuven - Campus Gasthuisberg, Leuven
Roswell Park Cancer Institute, Buffalo
University of Maryland Greenebaum Cancer Center, Baltimore
Wake Forest Baptist Health, Winston-Salem
University Hospitals Cleveland Medical Center, Cleveland
Washington University, St Louis
Klinikum der Universität München Campus Großhadern, München
Universitatsklinikum Ulm, Ulm
University of California Los Angeles, Los Angeles
City of Hope National Medical Center, Duarte
Universitätsklinikum Würzburg, Würzburg
Princess Margaret Cancer Centre, Toronto
Lead Sponsor
Amgen
INDUSTRY